FDA Approves Itvisma for Spinal Muscular Atrophy

MONDAY, Dec. 8, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal